ALNY Valuation

Alnylam Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

457.615

+3.645(0.803%)1D

ALNY Relative Valuation

ALNY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ALNY is overvalued; if below, it's undervalued.

Historical Valuation

Alnylam Pharmaceuticals Inc (ALNY) is now in the Fair zone, suggesting that its current forward PS ratio of 452.74 is considered Fairly compared with the five-year average of -45.32. The fair price of Alnylam Pharmaceuticals Inc (ALNY) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：453.97

Fair

72.06

Trailing

Forward

67.10

EV/EBITDA

Alnylam Pharmaceuticals Inc. (ALNY) has a current EV/EBITDA of 67.10. The 5-year average EV/EBITDA is -7556.17. The thresholds are as follows: Strongly Undervalued below -125560.31, Undervalued between -125560.31 and -66558.24, Fairly Valued between 51445.89 and -66558.24, Overvalued between 51445.89 and 110447.96, and Strongly Overvalued above 110447.96. The current Forward EV/EBITDA of 67.10 falls within the Historic Trend Line -Fairly Valued range.

57.07

EV/EBIT

Alnylam Pharmaceuticals Inc. (ALNY) has a current EV/EBIT of 57.07. The 5-year average EV/EBIT is -78.40. The thresholds are as follows: Strongly Undervalued below -1594.14, Undervalued between -1594.14 and -836.27, Fairly Valued between 679.46 and -836.27, Overvalued between 679.46 and 1437.33, and Strongly Overvalued above 1437.33. The current Forward EV/EBIT of 57.07 falls within the Historic Trend Line -Fairly Valued range.

453.97

Alnylam Pharmaceuticals Inc. (ALNY) has a current PS of 453.97. The 5-year average PS is 20.69. The thresholds are as follows: Strongly Undervalued below -71.97, Undervalued between -71.97 and -25.64, Fairly Valued between 67.02 and -25.64, Overvalued between 67.02 and 113.35, and Strongly Overvalued above 113.35. The current Forward PS of 453.97 falls within the Strongly Overvalued range.

48.21

P/OCF

Alnylam Pharmaceuticals Inc. (ALNY) has a current P/OCF of 48.21. The 5-year average P/OCF is 103.79. The thresholds are as follows: Strongly Undervalued below -592.46, Undervalued between -592.46 and -244.34, Fairly Valued between 451.91 and -244.34, Overvalued between 451.91 and 800.04, and Strongly Overvalued above 800.04. The current Forward P/OCF of 48.21 falls within the Historic Trend Line -Fairly Valued range.

54.63

P/FCF

Alnylam Pharmaceuticals Inc. (ALNY) has a current P/FCF of 54.63. The 5-year average P/FCF is -74.68. The thresholds are as follows: Strongly Undervalued below -1790.59, Undervalued between -1790.59 and -932.63, Fairly Valued between 783.27 and -932.63, Overvalued between 783.27 and 1641.22, and Strongly Overvalued above 1641.22. The current Forward P/FCF of 54.63 falls within the Historic Trend Line -Fairly Valued range.

Alnylam Pharmaceuticals Inc (ALNY) has a current Price-to-Book (P/B) ratio of 255.10. Compared to its 3-year average P/B ratio of -1094.86 , the current P/B ratio is approximately -123.30% higher. Relative to its 5-year average P/B ratio of -647.62, the current P/B ratio is about -139.39% higher. Alnylam Pharmaceuticals Inc (ALNY) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -0.55%, the current FCF yield is approximately -100.67% lower. Relative to its 5-year average FCF yield of -1.77% , the current FCF yield is about -100.21% lower.

255.80

P/B

Median3y

-1094.86

Median5y

-647.62

0.00

FCF Yield

Median3y

-0.55

Median5y

-1.77

Competitors Valuation Multiple

The average P/S ratio for ALNY's competitors is 290.90, providing a benchmark for relative valuation. Alnylam Pharmaceuticals Inc Corp (ALNY) exhibits a P/S ratio of 453.97, which is 56.05% above the industry average. Given its robust revenue growth of 149.35%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ALNY.O

Alnylam Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Ascentage Pharma Group International

239.55

12.57B

Performance Decomposition

Market capitalization of ALNY increased by 79.39% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 500.92M to 1.25B.

The secondary factor is the P/E Change, contributed 120.30%to the performance.

Overall, the performance of ALNY in the past 1 year is driven by Revenue Growth. Which is more sustainable.

149.35%

500.92M → 1.25B

Revenue Growth

-190.26%

-22.27 → 20.10

Margin Expansion

120.30%

624.73 → 1.38K

P/E Change

79.39%